The acute crisis, physicians concluded, was an episode of acute kidney injury superimposed on advanced, previously unrecognized chronic kidney disease, precipitated by the dehydration of her gastrointestinal illness. She had never undergone renal ultrasound, biochemical kidney function testing, or assessment of her estimated glomerular filtration rate, because she had never before sought medical care for her underlying condition. The case, published as a case report in Clinical Case Reports, documents how a rare multisystem genetic disorder called Bardet–Biedl syndrome went entirely undiagnosed into adulthood, allowing progressive kidney damage to accumulate unchecked until a routine infection brought the hidden disease to the surface.

Bardet–Biedl syndrome is a rare autosomal recessive ciliopathy, meaning it arises from defects in the primary cilium, a tiny antenna-like organelle that projects from nearly every cell in the body and coordinates crucial developmental and signaling pathways. The syndrome is defined by a constellation of features: rod–cone dystrophy of the retina that typically begins as night blindness and progresses to blindness, central obesity, extra fingers or toes known as polydactyly, intellectual disability, hypogonadism or genitourinary anomalies, and kidney involvement. Because the condition shows variable penetrance, its presentation can differ dramatically even among siblings in the same family, complicating recognition. In European outbred populations, prevalence is estimated at roughly one in 125,000 to one in 160,000 people, but isolated communities with founder mutations can carry far heavier burdens, most famously the Faroe Islands, where a single BBS1 splice-site mutation produces a prevalence of one in 3,700.

The patient in Lahore carried nearly the full textbook picture. Blind since age 19 after night blindness first appeared at age 8, she had a body mass index of 29, primary amenorrhea, childhood intellectual disability, bilateral polydactyly of both hands and feet, widely spaced eyes, strabismus, and a history of cystostomy for urethral stricture. Two of her siblings were affected by a similar constellation of problems, and she was born to first-cousin parents, a consanguinity pattern that dramatically raises the probability of homozygosity for recessive disease alleles. Laboratory workup added further findings: severe macrocytic anemia with hemoglobin of 6.8 g/dL, elevated alkaline phosphatase at 480 U/L, and an HbA1c of 8.2 percent with random glucose of 250 mg/dL, indicating poorly controlled diabetes mellitus that had also escaped prior diagnosis.

Imaging sealed the clinical picture. Abdominal ultrasound showed coarse liver echotexture, mild splenomegaly, and kidneys with increased echogenicity and reduced corticomedullary differentiation, hallmarks of chronic parenchymal damage. Computed tomography of the kidneys, ureters, and bladder then demonstrated bilaterally small kidneys, the right measuring 83 by 27 millimeters and the left 83 by 33 millimeters, with lobulated, irregular cortices consistent with longstanding scarring. In a young adult, kidneys of this size and texture represent years of accumulated nephron loss. The combination of retinal dystrophy, kidney disease, polydactyly, obesity, intellectual disability, primary amenorrhea, and affected siblings pointed decisively toward a hereditary ciliopathy, and the principal differential, Alström syndrome, was excluded because it does not typically involve polydactyly or intellectual disability. A clinical diagnosis of Bardet–Biedl syndrome was made, though genetic confirmation was not pursued because of resource limitations.

At the molecular level, BBS is strikingly heterogeneous: at least 26 genes have been identified, most encoding proteins essential for ciliary assembly and intracellular trafficking. Disruption of ciliary signaling, including the non-canonical Wnt pathway, is implicated in the cystogenesis and progressive nephron loss that characterize BBS-related kidney disease. Genotype–phenotype studies suggest that patients with variants in chaperonin-like genes such as BBS6, BBS10, and BBS12 tend to develop more severe chronic kidney disease than those with BBS1 variants, a finding that could eventually guide how intensively clinicians surveil renal function once sequencing becomes accessible in settings like Pakistan. Diagnostic criteria originally proposed by Beales and colleagues require either four primary features or three primary features plus two secondary ones, and a recent European Reference Networks consensus has updated the framework to incorporate molecular diagnosis alongside clinical findings. This patient fulfilled the primary criteria of rod–cone dystrophy, postaxial polydactyly, obesity, intellectual disability, genitourinary anomalies, and renal dysfunction.

What makes the case exceptional is timing. The mean age of clinical BBS diagnosis is around nine years, yet this patient reached her third decade without a formal syndromic diagnosis of any kind. Renal involvement affects more than half of BBS patients and is the leading driver of premature mortality in the syndrome, ranging from structural anomalies such as fetal lobulation and increased parenchymal echogenicity to cystic dysplasia and progressive loss of glomerular filtration. In the largest reported cohort, kidney failure requiring renal replacement therapy occurred in roughly 6 percent of adult and 5 percent of pediatric patients, and affected children tend to follow one of two trajectories, either developing severe chronic kidney disease early or remaining comparatively spared through childhood. An early warning sign, reduced urinary concentrating capacity producing polyuria and polydipsia, reflects tubular dysfunction tied to disrupted ciliary signaling and can flag declining renal function years before crisis.

Treatment of the acute episode followed standard nephrology practice. The patient received three sessions of hemodialysis, broad-spectrum antibiotics, intravenous fluids, and antipyretics, and improved over subsequent days with a notable recovery of urine output before discharge with strict follow-up advice. Her echocardiogram was normal, reassuring given that cardiovascular abnormalities have been documented in a subset of BBS patients. Longer-term management of the syndrome demands a genuinely multidisciplinary approach spanning nephrology, ophthalmology, endocrinology, genetics, and cardiology, with regular blood pressure monitoring, annual ophthalmologic evaluation, and periodic assessment of renal and metabolic parameters. Should her kidneys progress to outright failure, renal transplantation remains viable with outcomes comparable to the general population, although coexisting obesity can complicate both pre-transplant workup and post-transplant metabolic management. No disease-modifying therapy yet exists for the renal or retinal manifestations, making surveillance the principal tool for delaying irreversible complications.

The Pakistani context adds a public-health dimension. Roughly half to two-thirds of marriages in the country are consanguineous, most commonly between first cousins, a pattern that should, in principle, elevate the prevalence of autosomal recessive disorders like BBS. Yet reported Pakistani cases remain scarce, a paradox the report’s authors attribute to underdiagnosis rather than genuinely low prevalence, driven by limited access to ophthalmologic, nephrologic, and genetic testing. A recent case series from Multan described four affected individuals from two sibling pairs, illustrating both marked intrafamilial variability and diagnostic delay, and the literature now includes scattered reports from Dera Ismail Khan, Peshawar, Karachi, and Islamabad. Most patients present in childhood or adolescence with retinal and developmental features and are diagnosed clinically rather than genetically, and the present case appears to be among the few from Pakistan in which unrecognized chronic kidney disease progressed to acute kidney injury in adulthood before the underlying syndrome was ever identified.

The broader lesson reaches beyond one hospital ward. Bardet–Biedl syndrome’s features can appear so scattered across specialties, an eye problem here, extra digits there, obesity and developmental delay elsewhere, that no single clinician assembles the full picture until something acute forces the issue. Greater awareness among pediatricians, ophthalmologists, and family physicians, combined with systematic renal surveillance of children showing the syndrome’s cardinal features, could allow earlier diagnosis and potentially forestall exactly the kind of delayed, dramatic presentation seen in Lahore. Genetic counseling remains central to comprehensive care, informing families about recurrence risk and the value of screening apparently healthy relatives for subclinical complications. For this 27-year-old woman, the gastroenteritis that nearly overwhelmed her kidneys also finally gave her disease a name, and with it, at last, the possibility of coordinated care.

Subject of Research: Bardet–Biedl syndrome presenting as acute kidney injury on undiagnosed chronic kidney disease in a young adult

Article Title: Bardet–Biedl Syndrome Presenting With Acute Kidney Injury Revealing Previously Undiagnosed Advanced Chronic Kidney Disease in a Young Adult: A Case Report

Article References: Abbas, A., Amjad, N., Mufti, A. F., Waqas, M., Iqbal, M., Ali, H., Habib, A., Samadi, Y., & Haider, M. U. (2026). Bardet–Biedl Syndrome Presenting With Acute Kidney Injury Revealing Previously Undiagnosed Advanced Chronic Kidney Disease in a Young Adult: A Case Report. Clinical Case Reports, 14(10), Article e73672. https://doi.org/10.1002/ccr3.73672

Image Credits: AI Generated

DOI: 10.1002/ccr3.73672

Keywords: Bardet-Biedl syndrome, ciliopathy, acute kidney injury, chronic kidney disease, polydactyly, rod-cone dystrophy, consanguinity, Pakistan, hemodialysis, genetic diagnosis, primary cilium, rare disease

The biology underlying these conditions centers on the melanocortin 4 receptor pathway, a critical signaling cascade in the hypothalamus that governs energy balance and appetite. Under normal circumstances, the hormone leptin binds to leptin receptors on the surface of pro-opiomelanocortin neurons, triggering a chain of signaling that ultimately activates melanocortin 4 receptor neurons. These neurons send satiety signals that suppress food intake and increase energy expenditure. When any step in this pathway fails, whether through a genetic mutation in the leptin receptor gene, loss of pro-opiomelanocortin production, the pleiotropic genetic disruptions of Bardet-Biedl syndrome, or structural damage to the hypothalamus itself, the result is hyperphagia: a chronic, pathological state of insatiable hunger and impaired satiety that drives persistent food-seeking behavior and severe, early-onset obesity.

Until recently, there was no effective treatment aimed at this pathway, and no universally accepted way to measure hunger from the patient’s perspective. Existing appetite questionnaires were developed for people with common obesity who have intact melanocortin signaling, making them poorly suited to capture the extreme hunger experienced by patients with pathway diseases. That changed with the development of setmelanotide, an MC4R agonist that is currently the only US Food and Drug Administration-approved therapy targeting this pathway in patients aged two years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome, leptin receptor deficiency, pro-opiomelanocortin deficiency, or acquired hypothalamic obesity. In phase 3 trials, patients treated with setmelanotide achieved significant weight loss alongside marked reductions in hunger, making hunger itself a legitimate and important treatment outcome.

To measure that outcome, researchers created the Daily Hunger Questionnaire, a three-item patient-reported instrument addressing morning hunger, average hunger, and the single most intense hunger experienced over the previous 24 hours. The Most Hunger item, which asks patients to rate their peak hunger on an 11-point scale from zero, meaning not hungry at all, to ten, meaning hungriest possible, was designated a key secondary endpoint in the setmelanotide phase 3 trials under agreements with the FDA’s Division of Diabetes, Lipid Disorders, and Obesity. The new study set out to establish whether this item truly works: whether patients understand it, whether it produces consistent and meaningful scores, and how much change on the scale represents a difference that patients actually feel.

The qualitative phase involved three separate interview studies, each aligned with FDA guidance on patient-focused drug development. Patients with leptin receptor or pro-opiomelanocortin deficiency were interviewed face-to-face at a German clinical site before entering the setmelanotide trials, while patients with Bardet-Biedl syndrome and acquired hypothalamic obesity were interviewed by telephone or video after participating in their respective trials, allowing them to compare hunger before and during treatment. Cognitive debriefing confirmed that participants across all three groups understood the Most Hunger item and could answer it with reasonable consistency. When asked to describe what a ten on the scale meant, patients spoke of an unrelenting hunger that impaired their ability to function, while a five was generally considered a tolerable level. Participants with Bardet-Biedl syndrome reported a mean pre-treatment score of 8.8, and those with acquired hypothalamic obesity reported a mean of 8.5, scores that patients associated with an all-consuming desire for food and extreme food-seeking behaviors such as sneaking or hiding food.

The quantitative phase analyzed data from four phase 3 trials, registered under ClinicalTrials.gov identifiers NCT03287960, NCT02896192, NCT03746522, and NCT05774756. Participants recorded their hunger daily at home using an electronic diary for seven consecutive days before each clinic visit, and weekly averages were computed for analysis. At baseline, mean weekly Most Hunger scores ranged from 6.9 to 7.5 across the disease groups, and by the end of treatment, patients had improved by an average of 2.3 to 3.3 points. Test-retest reliability, assessed by comparing scores from two consecutive weeks in the absence of any expected change, yielded intraclass correlation coefficients of 0.51 for the pooled leptin receptor and pro-opiomelanocortin deficiency group, 0.59 for Bardet-Biedl syndrome, and 0.80 for acquired hypothalamic obesity. The authors note that the lower estimates in the rarer genetic diseases likely reflect the very small samples and the homogeneity of responses, which can depress reliability statistics, rather than any inherent flaw in the measure.

Construct validity was supported by convergent correlations between the Most Hunger item and the Patient Global Impression of Severity, a four-point anchor measure administered at clinic visits. In the leptin receptor and pro-opiomelanocortin deficiency group, correlations with the PGIS were strong at later timepoints, reaching 0.75 at week 13 and 0.86 at week 53, while the acquired hypothalamic obesity group showed a strong baseline correlation of 0.74 and a moderate to high end-of-treatment correlation of 0.57. Known-groups analyses in the hypothalamic obesity cohort showed statistically significant differences in Most Hunger scores across PGIS severity categories, with mean scores falling from 7.0 in the moderate hunger group to 4.9 in the mild hunger group at baseline. In the Bardet-Biedl syndrome population, however, correlations with the PGIS were negligible, a discrepancy the authors attribute to ceiling effects on the hunger item and restricted use of the PGIS severity categories, which limited the ability to detect associations.

Perhaps the most clinically consequential output of the study is the estimation of meaningful within-patient change thresholds, the amount of score change that corresponds to a difference patients perceive as meaningful. Using anchor-based methods with a one-point improvement on the PGIS and the much less hungry category of the Patient Global Impression of Change as anchors, the researchers estimated thresholds of 1.5 to 2.6 points for patients with leptin receptor or pro-opiomelanocortin deficiency and 2.4 to 3.7 points for those with acquired hypothalamic obesity. For Bardet-Biedl syndrome, weak responsiveness between the Most Hunger item and the global anchors prevented direct estimation, so the team turned to the closely correlated Morning Hunger item, deriving a preliminary threshold range of 0.95 to 1.6 points. The authors caution that because the trial populations and designs differed, these thresholds should not be compared across diseases as indicators of differing treatment sensitivity; they simply provide context for interpreting individual patient improvement in future trials.

Beyond the psychometrics, the study delivers a striking portrait of what it feels like to live with a broken satiety pathway. Across all four diseases, patients described essentially the same experience: scores of seven to nine before treatment, an intrusive and relentless preoccupation with food, and behaviors consistent with hyperphagia. After setmelanotide, mean weekly scores settled between four and five, and patients described the reduction as life changing, reporting improved focus and mood, decreased food-related anxiety, better family and social relationships, and renewed participation in hobbies and interests. The convergence of qualitative and quantitative evidence across such distinct etiologies, genetic and acquired alike, strengthens confidence that the Most Hunger item captures a shared, biologically grounded phenomenon rather than a disease-specific quirk.

The work also has clear forward momentum. On the basis of the evidence supporting the item in patients aged 12 and older, the team reports that a caregiver-reported version for children under 12 is currently in development, extending the measurement framework to younger patients who often bear the earliest and heaviest burden of these diseases. Limitations remain, including the small samples inherent to rare disease research, the absence of sex and gender analyses, and potential recall bias in interviews conducted at varying intervals before treatment or before hypothalamic injury. The psychometric analyses also used blinded pooled data across treatment and placebo groups and were not designed to evaluate efficacy. Even so, the study establishes the Most Hunger item as a fit-for-purpose patient-reported outcome for measuring hunger in MC4R pathway diseases, giving future trials a validated yardstick for one of the most disabling symptoms in medicine and giving patients a way to make an invisible, internal experience count in the evaluation of new therapies.

Subject of Research: Development and psychometric validation of a patient-reported hunger measure for rare MC4R pathway obesity diseases

Article Title: Measuring Hunger Severity in Rare MC4R Pathway Diseases: Development and Psychometric Evaluation of the Most Hunger Item

Article References: Clément, K., Roth, C. L., Kühnen, P., Haqq, A. M., Mallya, U. G., Ervin, C., Norcross, L., Bhargava, S., Argente, J., & Miller, J. L. (2026). Measuring Hunger Severity in Rare MC4R Pathway Diseases: Development and Psychometric Evaluation of the Most Hunger Item. Advances in Therapy. https://doi.org/10.1007/s12325-026-03741-x

Image Credits: AI Generated

DOI: 10.1007/s12325-026-03741-x

Keywords: MC4R pathway, hyperphagia, setmelanotide, Bardet-Biedl syndrome, POMC deficiency, LEPR deficiency, hypothalamic obesity, patient-reported outcome, psychometric validation, rare disease, obesity, hunger measurement

The review, led by researchers including Peiwei Liu and supported by the National Natural Science Foundation of China, assembles evidence from mass spectrometry studies of isolated cilia in mammals and unicellular organisms to sketch the first broad map of ciliary membrane lipids. Primary cilia isolated from kidney-derived MDCK cells are enriched in cholesterol and its precursor desmosterol, apparently to reinforce membrane microdomains used for signal transduction. Motile cilia from porcine olfactory epithelium tell a different story: they lack cardiolipin, carry reduced amounts of phosphatidylethanolamine, and are enriched in sulfoglycosphingolipids, an adaptive profile thought to optimize the membrane for the mechanical stress of beating. In single-celled organisms the diversity is even more striking. The flagellar membrane of Trypanosoma brucei is rich in phosphatidylethanolamine, phosphatidylserine, ceramides, and sphingomyelin, while Chlamydomonas reinhardtii concentrates phytoceramide and ergosterol, lipids suited to photophysical processes and to ordered microdomains at the flagellar base.

Perhaps the most visually compelling finding concerns phosphoinositides, phosphorylated derivatives of phosphatidylinositol that form exquisitely organized rings within the cilium. Phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate localize to the transition zone, the molecular sieve at the ciliary base, where they occupy distinct subregions along the proximal-distal axis: PI(4,5)P2 sits closer to the basal body while PI(3,4,5)P3 occupies the distal portion. Phosphatidylinositol 4-phosphate, by contrast, is excluded from the transition zone and accumulates toward the ciliary tip. This polarized geography is not decorative. PI4P directly binds the C-terminus of the signaling protein Smoothened, driving the conformational change and phosphorylation required for Hedgehog pathway activation, one of the most conserved developmental signaling systems in animals. Cholesterol, meanwhile, can itself activate Smoothened through multiple binding domains, and its release from the receptor Patched 1 upon Hedgehog ligand binding is a central step in the cascade.

The review also confronts a stubborn technical controversy. Measurements of ciliary PI(4,5)P2 have produced conflicting results for years, with some studies detecting the lipid along the entire axoneme and others confining it strictly to the transition zone. The authors trace these discrepancies to permeabilization methods, microscopy techniques, and differences between antibodies and genetically encoded biosensors. Methanol fixation followed by confocal imaging spreads the signal along the axoneme, whereas Triton X-100 permeabilization or super-resolution STED microscopy restricts it to the transition zone. The field has not even agreed on whether low-level ciliary PI(4,5)P2 is physiological or pathological. The authors call for quantitative mass spectrometry, correlative light-electron microscopy, artificial intelligence-assisted artifact correction, and absolutely calibrated biosensors to settle the debate.

Beyond phosphoinositides, the review highlights cholesterol sequestration as a surprising regulatory mechanism. Using newly developed protein probes derived from bacterial toxins, researchers compared the ciliary membrane with the adjacent plasma membrane and found that the ratio of sphingomyelin to cholesterol is far higher in cilia, with accessible cholesterol present at extremely low levels. In other words, abundant sphingomyelin chelates cholesterol into a chemically inactive state. When sphingomyelin synthesis is inhibited, the trapped cholesterol is released and Hedgehog signaling is enhanced. This finding reframes the ciliary membrane as a buffered reservoir of sterol whose availability, not just abundance, controls signal output. Lipid rafts, the cholesterol- and sphingolipid-rich microdomains concentrated at the ciliary base, serve as platforms that gather GPI-anchored and acylated proteins, amplifying signaling, although the review notes that some ciliary proteins, such as adenylyl cyclase III and INPP5E, reach their destinations even when rafts are disrupted.

Lipids also act as molecular switches for building and dismantling the organelle itself. Phosphatidylserine on the trans-Golgi network recruits Rabin8 to initiate ciliary formation. Ceramides accumulate in an apical ceramide-enriched compartment above the basal body, and the enzyme SMPD4, which generates ceramide from sphingomyelin, is required for normal ciliary length; mutations in SMPD4 cause cilia shortening and are linked to cerebellar hypoplasia. Centrosomal PI4P must be cleared by the kinase PIPKIγ to allow recruitment of ciliogenesis factors such as TTBK2, while Golgi PI4P must be maintained by PI4KB to release Rab11a for delivery to centrioles. Distal PI(4,5)P2 controls ciliary length by regulating vesicle shedding at the tip. Even diet matters: a high-fat diet upregulates the enzyme SCD1, depleting palmitic acid needed for palmitoylation of ciliary proteins such as ARL13B and RAB8A in endothelial cells, while the same fatty acid accumulates in hypothalamic neurons, suppressing autophagy and shrinking their cilia. The microbiota-derived short-chain fatty acid butyrate, in contrast, promotes ciliogenesis in hunger-regulating neurons.

The clinical payoff of this basic science is substantial. In Bardet-Biedl syndrome, mutations in more than twenty genes disrupt the BBSome, a protein complex that balances lipid and protein traffic between the plasma membrane and the cilium. Loss of bbs1 in zebrafish photoreceptors causes free cholesterol to accumulate, and BBSome deficiency allows enzymes such as phospholipase D to build up inside cilia, altering their lipid composition. The authors propose a Fish Trap model in which the transition zone admits membrane proteins freely but blocks their exit, making BBSome-mediated export the only rescue route. In autosomal dominant polycystic kidney disease, cholesterol binding is essential for localizing the ion channel polycystin-2 to cilia, and the oxysterol 7β,27-dihydroxycholesterol gates the polycystin complex. Glycosphingolipids such as glucosylceramide and lactosylceramide are markedly elevated in polycystic kidneys. Zellweger syndrome, caused by peroxisome failure, starves cilia of cholesterol because peroxisomes normally ferry sterol along microtubules to the ciliary pocket, crippling Hedgehog signaling.

Phosphoinositide disorders complete the picture. Joubert syndrome, marked by the molar tooth sign on brain imaging, frequently stems from mutations in INPP5E, the enzyme that removes PI(4,5)P2 and PI(3,4,5)P3 from cilia. Without it, these lipids accumulate, disrupting the recruitment of the cargo adaptor TULP3 and derailing Hedgehog signaling. Intriguingly, different mutations in the same gene produce different diseases: catalytic-domain variants preserve ciliary targeting and cause Joubert syndrome, whereas C-terminal truncations destroy targeting but spare enzymatic activity, producing MORM syndrome with obesity and intellectual disability. Hydrolethalus syndrome, a lethal fetal ciliopathy, arises when mutant HYLS1 fails to activate PIPKIγ and clear centrosomal PI4P, simultaneously blocking ciliogenesis and Hedgehog signaling.

Therapeutically, the lipid angle is already yielding drugs. The glucosylceramide synthase inhibitor Genz-667161 alleviated obesity, retinal degeneration, and olfactory deficits in BBS mice while restoring ciliary structure and Hedgehog activity, and the related inhibitor Venglustat slowed cyst progression in polycystic kidney disease models. The approved MC4R agonist setmelanotide remains the core targeted therapy for BBS, though it requires dermatologic monitoring, and antisense oligonucleotides have restored protein expression in preclinical models of BBS16 splicing defects. A ketogenic diet improved kidney function in the KETO-ADPKD trial, and the PI3K inhibitor LY294002 partially rescued ciliary defects in zebrafish lacking inpp5e. The authors point to three frontiers: cryo-electron microscopy to resolve lipid-protein complexes at atomic resolution, deeper study of the cilia-metabolism axis linking ciliary dysfunction to obesity and dyslipidemia, and dynamic mapping of ciliary lipid rafts with spatial lipidomics and super-resolution imaging. What was once an afterthought of cilia biology, the membrane itself, is now the most promising therapeutic frontier in the field.

Subject of Research: Lipid homeostasis of the ciliary membrane and its role in cilia function and ciliopathies

Article Title: Ciliary Membrane Lipid Homeostasis in Health and Disease

Article References: Ciliary Membrane Lipid Homeostasis in Health and Disease. (n.d.). https://doi.org/10.1002/advs.77971

Image Credits: AI Generated

DOI: 10.1002/advs.77971

Keywords: cilia, ciliary membrane, lipids, cholesterol, phosphoinositides, ceramide, Hedgehog signaling, ciliopathies, Bardet-Biedl syndrome, polycystic kidney disease, Joubert syndrome, lipid rafts